

10-17-02

1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Egrie et al.

Serial No.: 09/559,001

Group Art Unit No.: 1646

Filed: April 21, 2000

Examiner: Unknown

For: Methods and Compositions for the Prevention and Treatment of Anemia

Docket No.: A-460A



#17
D.G.J.
10/23/02
RECEIVED

OCT 21 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BEFORE
MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97(c))

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A ☐ a statement as specified in 37 CFR 1.97(e):

10/18/2002 ANABII 00000100 010519 09559001

STATEMENT

01 FC:1806

180.00 CH

I, the person(s) signing below state:

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360691774US

Date of Deposit: October 15, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

SL. ST. ANDREW
Printed Name

SL. ST. ANDREW
Signature

- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).


Applicants request consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicants
Registration No.: 34,458
Phone: (805) 447-2425
Date: October 15, 2002

Please send all future correspondence to:

US Patent Operations/ [RBW]
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799